Latest News & Features
Careers
IP specialist joins firm’s Bristol office | Transaction expert has advised AstraZeneca, Cancer Research Horizons, and other high-profile clients. 14 January 2025
Big Pharma
Federal circuit reverses district court’s ruling to revive combination patent | Novartis says patent has paediatric exclusivity expiring in July 2025. 14 January 2025
Europe
Company faces setback as EPO revokes patent for a C1-esterase inhibitor treatment | Patent aims at preventing antibody-mediated rejection in kidney transplant patients | Court cites insufficient clinical trial data. 9 January 2025
Careers
Skilled in microbiome, medical devices and next generation diagnostics, the new partner is skilled in creating IP strategies for startups, spinouts and SMEs. 9 January 2025
Americas
PTAB determines all but one of challenged claims unpatentable | Decision is latest instalment in clash over electrocardiogram technology | Apple bid to stop ‘AliveCor’s rampant infringement’ backfires. 9 January 2025
Americas
Case concerns allegations that ex-senior vice president of business development at Skye Orthobiologics misappropriated secrets and breached contract | Companies in dispute process and manufacture medical products derived from human placental tissue. 7 January 2025
Americas
Biotech walks away with another win as Fed Circ upholds PTAB decision | Labcorp’s attempt to overturn $373m verdict fails | Court finds Ravgen’s method for preserving DNA in blood samples not obvious. 7 January 2025
Careers
Two large teams leave Locke Lord following Troutman Pepper merger | Buchanan opens Chicago office with a large life sciences group | Shoosmiths adds team in London to expand brand-focused IP services. 7 January 2025
Careers
New partner brings technical background in computer science and more than a decade experience in patent litigation | Expertise in tech, engineering, chemical, and life sciences sectors. 7 January 2025
Americas
The Japanese pharma company files complaint against Lupin Pharmaceuticals | Suit alleges patent infringement over the company’s proposed generic version of a key ALS drug. 2 January 2025